Reuters exclusively reports EU secures potential COVID-19 drugs from Roche, Germany’s Merck

Reuters exclusively reported that the European Commission has struck deals with drugmakers Roche and Merck KGaA to secure supplies of experimental treatments for COVID-19. The deals cover Roche’s arthritis drug RoActemra and Merck’s multiple sclerosis drug Rebif – both seen as potential COVID-19 therapies – and will secure supplies for any of the 27 European Union member states wanting to buy them.